New treatment funded for Acute Lymphocytic Leukaemia

As of 1st May 2019 Inotuzumab (Besponsa) will be available on the PBS for patients with relapsed acute lymphocytic leukaemia (ALL) or refractory CD22 positive B-cell precursor ALL. The treatment costs $120,000 per course but due to funding you will only pay $40.30 or $6.50 (for concession card holders) a course.

Acute lymphocytic leukaemia occurs in approximately 300 adults and children every year with children accounting for 60% of the cases.